News Hims & Hers launches weight-loss business in UK Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.
News Novo Nordisk's fling with Hims & Hers ends in a bust-up The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.
News Hims & Hers buys Zava to form European beachhead US telehealth company Hims & Hers has reached a deal to buy its UK counterpart Zava as part of a broader push into Europe.
News Novo Nordisk unleashes Wegovy telehealth blitz Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.
News Compounders cast adrift after semaglutide shortage ends The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
News Pharma group slams Hims & Hers over Super Bowl GLP-1 ad Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
